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Recently, cancer mortality has been compared to research spending by the National Cancer Research Institute (NCRI), whose
research budget is approximately d250 million. The analysis shows a mis-match between mortality and research spending. As well as
crude mortality rates, other measures of cancer burden should be considered because they contribute additional information. ‘Years
of life lost’ (YLL) summed over each individual dying after a diagnosis of cancer represents a population-based mortality indicator of
the impact of that disease on society. Years of life lost divided by the number of deaths for each cancer site produces an additional
statistic, the average years of life lost (AYLL), which is a measure of the burden of cancer to the individual patient. For 17 cancer sites
where data are available, four tumour sites have a rather large difference in mortality, comparing YLL to crude mortality. Years of life
lost shows the population burden from cancers of the ovary, cervix, and CNS to be rather larger than suggested by crude mortality,
despite screening programmes for cervix cancer. Using YLL, the underprovision of funding for lung cancer research is similar to that
reported using percentage mortality. Breast cancer and leukaemia receive a relatively higher research spend than the population
burden of these cancers, and the spending on leukaemia is quite extreme. Prostate cancer has a low per cent YLL but attracts a
moderate amount of research spending. The use of AYLL as an indicator of individual cancer burden considerably changes the ranking
of the mortality from different tumours. The mean AYLL is 12.5 years. Prostate cancer has the lowest AYLL, only 6.1 years; brain
tumour patients have the highest, at just over 20 years. Comparing AYLL to research spending suggests four ‘Cinderella’ cancer sites
with high individual cancer burden but low research spending: CNS tumours, cervix and kidney cancers, and melanoma. Breast cancer
and leukaemia have roughly average AYLL but a considerable excess of research spending. YLL emphasises the discrepancy between
research spending and mortality, and may be helpful for decisions concerning research support. Avearage years of life lost measures
the burden to individual patients and may be helpful where individuals’ needs are relevant, such as palliative care. As well as crude
mortality, more subtle and comprehensive calculations of mortality statistics would be useful in debates on research funding and
public health issues.
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Measures of mortality from all types of diseases are clearly
important for public health considerations. With regards to cancer
mortality, data are important to monitor the effects of screening
programmes, efforts at earlier diagnosis and treatment, and the
effects of environmental and other causative factors such as
smoking. Recently, mortality from cancer has also been compared
to research spending by the National Cancer Research Institute
(NCRI) as a means to gauge the appropriate relative level of
expenditure for different tumour sites, and to inform debate about
the distribution of funds (BMJ News, 2002; NCRI, 2002).
The latest figures on cancer mortality from Cancer Research UK
(Cancer Research UK, 2004) suggest that in the last decade (1993 to
2002) there has been an overall reduction in cancer mortality rates
in both men and women. This has been achieved by a reduction in
mortality from the majority of cancers, including those which are
most common. There are, however, some noticeable exceptions to
this, principally affecting men with melanoma, kidney cancer,
oesophageal cancer and tumours of the brain and CNS. None of
these tumour sites has attracted more than 3% of NCRI research
spending, despite the increase in mortality associated with these
tumours.
There have been valuable efforts by the NCRI to review funding
in relation to mortality, leading to the publication of a strategic
analysis (NCRI, 2002). This strategic analysis clearly shows a mis-
match between mortality and research spending, particularly for
lung cancer which is under-resourced, and for leukaemia which
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sappears to be over-resourced. The overall research budget is
approximately d250 million (BMJ News, 2002; NCRI, 2002) so the
analysis has important implications, both for the NCRI overall and
for researchers on individual tumour types. Within the context
that mortality rates might influence cancer spending, it is
important to consider the details of the measure of the mortality
used. As well as crude mortality rates, other measures of cancer
burden should be considered because they contribute additional,
potentially valuable information.
METHODS
Simple percentage mortality expresses the number of deaths from
an individual tumour type divided by the total number of deaths
from cancer as a percentage. However, another important
mortality statistic that complements crude mortality indicators is
‘years of life lost’ (YLL). This is calculated for each individual
dying after a diagnosis of cancer by subtracting the actual survival
since diagnosis from the individual’s life expectancy at the time of
diagnosis, based on appropriate life tables. The YLL for a specific
cancer site in a population is obtained by summing all the
individual years of life lost through deaths from the cancer of
interest, in that population in a specific time period. This can then
be expressed as a percentage, that is, the years of life lost from a
specific cancer as a percentage of the total number of years of life
lost from all cancers.
Therefore, YLL is a population-based mortality indicator, which
gives more weight to those diseases that kill early or are incurable.
Thus, weighting is given to cancers that affect patients at a young
age and who die as a result. It also counterbalances the weighting
given to common cancers in older patients by simple percentage
mortality. This combination of factors allows YLL to give an
indication of the impact of the disease on society, that is, it
represents the population burden for individual cancers.
Years of life lost
Data from the East Anglian Cancer Registry for the 5-year period
1990 to 1994 were used to calculate YLL. No cutoff for age was used
for the calculations. Although a cutoff at age 70 years has been
suggested (Romeder and McWhinnie, 1977), censoring patients
over 70 years is clearly unhelpful in the context of cancer mortality.
Years of life lost was evaluated for the population with cancer,
irrespective of whether or not they died from the cancer. The
statistics used for the calculation of life expectancy were obtained
from the 1990 East Anglia OPCS Life tables.
Data for 17 tumour types are available, which account for 84% of
the total YLL from cancer. The figure for colo-rectal cancer also
includes anal tumours. Specific YLL data for liver cancer, and head
and neck cancers are not available but they represent only 2% each
of simple mortality (NCRI, 2002). Unspecified ‘other’ tumour types
account for the remainder of cancer deaths, but these cannot be
specifically addressed in comparison to per cent YLL because of
the lack of detail.
Average years of life lost
Figures for YLL can be used to produce an additional mortality
statistic, the average years of life lost (AYLL). Average years of life
lost is simply an average derived by dividing YLL by the actual
number of deaths for each cancer site, over the defined time
period. This parameter is interesting because it provides a measure
of the burden of cancer to the individual patient, rather than the
population as a whole. Effectively it shows, on average, how much
a patient’s life is likely to be shortened by their cancer.
RESULTS
Years of life lost
The YLL for an individual cancer site can be expressed as a
percentage of the total years of life lost from all cancers, so it can
be directly compared with percentage mortality. Figure 1 shows a
simple plot of percentage of years of life lost vs percentage
mortality, for 17 cancer sites where YLL data are available. The
majority of points lie close to the line of equality. This graph shows
absolute differences in percentage for the two mortality indicators.
Since most of the tumour sites lie relatively close to the origin, the
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Figure 1 Years of life lost (YLL) vs crude mortality. This shows the difference between the two measures of deaths from cancer: YLL represents the
population burden from a specific cancer rather than the simple percentage of deaths from that tumour. The line of equality (y¼x) is shown, so that cancers
whose population burden exceed their simple mortality are shown above and to the left of the line. See also Table 1.
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sabsolute differences between them are quite small. Therefore, a
helpful way to express the difference between per cent YLL and per
cent mortality is to show the difference as a ratio.
Table 1 shows the percentage mortality and percentage of YLL,
as well as the ratio per cent YLL divided by per cent mortality,
arranged in order according to this ratio, for the 17 specified sites.
The figures are normalised to sum to 100% for these sites. Several
tumour types have very similar death rates with either mortality
indicator, and a number of others have relatively little difference
between the two measures. However, four tumour sites have a
rather large difference, with ratios o0.60 or 41.4, which is not
apparent from Figure 1. The population burden from prostate
cancer is rather less than that is suggested by per cent mortality.
On the other hand, the population burden of cancers of the ovary,
cervix and CNS is rather higher, despite the presence of a screening
programme for cervix cancer. Lung cancers are represented
similarly by percentage YLL and percentage mortality, so the ratio
is close to unity.
In Figure 2, the percentage of YLL has been plotted against the
percentage of NCRI research spend, for the 17 cancer sites. In
order to make comparison more informative, the figures for YLL
are now expressed as a percentage of the total YLL attributable to
cancer. The 17 specific sites account for 84% of YLL from cancer.
Tumour sites above and to the left of the line of equality have
greater YLL than research spend, while those below and to the
right have higher research spend relative to YLL. The positions of
breast cancer and leukaemia to the right of the figure indicate a
relatively higher research spend than the population burden of
these cancers, and the relative spending on leukaemia is quite
extreme. Prostate cancer has a lower per cent YLL but apparently
attracts a moderate amount of research spending. Conversely, lung
cancer attracts rather less research spending than its cancer
burden. Using YLL as the relevant mortality indicator, the
considerable underprovision of lung cancer research funding
remains.
Table 1 Percentage mortality and percentage of YLL for 17 specific
tumour sites
Site % YLL % Mortality % YLL/% mortality
Brain+CNS 4.1 2.3 1.78
Cervix 2.0 1.3 1.53
Ovary 4.3 3.0 1.44
Melanoma 1.7 1.3 1.33
Leukaemia 3.6 3.0 1.20
Breast 15.5 13.0 1.19
NHL 4.2 3.6 1.18
Kidney 2.4 2.1 1.13
Pancreas 4.3 4.1 1.05
Lung 21.7 20.9 1.04
Oesophagus 3.2 3.2 0.99
Stomach 6.2 6.4 0.98
Uterus 1.7 1.7 0.97
Myeloma 1.9 2.1 0.91
Colon+rectum (+anus) 14.5 16.5 0.87
Bladder 3.4 5.3 0.65
Prostate 5.5 10.2 0.54
Total 100 100
The relative difference between the two parameters of mortality is given by the ratio
% YLL/% mortality. Sites are shown in order of this ratio. Figures are presented only
for the 17 specified sites, and are therefore normalized to add up to 100%. Data for
head and neck cancer, liver cancer and ‘other’ unspecified tumours are not shown,
because YLL data are not available for these sites (data from the East Anglian Cancer
Registry). YLL¼years of life lost; AYLL¼avereage years of life lost.
% of YLL vs % NCRI research spend for 17 cancer sites
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Figure 2 Years of life lost (YLL) vs National Cancer Research Institute (NCRI) research spending. The line of equality (y¼x) is shown. The considerable
difference between population burden and research spending for some cancers is clear. The positions of breast cancer and leukaemia to the right of the
figure indicate a relatively higher research spend than the population burden of these cancers, and the relative spending on leukaemia is quite extreme.
Conversely, lung cancer attracts rather less research spending than its cancer burden. Assessing this ratio for the tumour sites near the origin of the graph is
better done numerically – see Table 2 for details.
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sThe diagram shows the outlier tumour sites clearly, but as with
Figure 1, a large number of tumour sites fall near the origin and are
not clearly distinguished. The data are therefore presented in
Table 2, where the ratio of the two parameters indicates the
similarity or discrepancy between them.
Table 2 Percentage of YLL and percentage of NCRI spending, for 17
tumour sites
Site % YLL % NCRI spend % YLL/% NCRI spend
Lung 18.2 3.5 5.2
Pancreas 3.6 1.0 3.6
Stomach 5.2 1.5 3.5
Uterus 1.4 0.5 2.8
Oesophagus 2.7 1.0 2.7
Brain+CNS 3.4 1.5 2.3
Bladder 2.9 1.5 1.9
Kidney 2.0 1.5 1.3
Myeloma 1.6 1.5 1.1
Colon+rectum (+anus) 12.0 12.0 1.0
Breast 13.0 18.0 0.7
NHL 3.5 5.5 0.6
Ovary 3.6 6.0 0.6
Prostate 4.7 8.5 0.5
Cervix 1.7 3.5 0.5
Melanoma 1.4 3.0 0.5
Leukaemia 3.0 17.5 0.2
Total 83.9 87.5
The ratio of the two gives an indication of the difference between population burden
of deaths from the individual cancers and the research spending on that tumour
group. Sites are shown in order of this ratio. For comparison, percentage mortality
divided by percentage of NCRI spending is also shown. For the top two sites, lung
and pancreas, the ratio of % YLL to research spending is less than the equivalent
figure using % mortality. However, for cancers of the stomach, uterus and CNS
(shown in bold), the opposite is true, and % YLL exceeds the % of spending on those
cancer sites. Data for head and neck cancer, liver cancer and ‘other’ unspecified
tumours are not shown, because YLL data are not available for these sites.
YLL¼years of life lost; AYLL¼avereage years of life lost; NCRI¼National Cancer
Research Institute.
Table 3 The AYLL per patient, for 17 tumour sites, in order of
descending AYLL
Site AYLL (years) % YLL
Brain+CNS 20.1 3.4
Cervix 17.3 1.7
Ovary 16.3 3.6
Melanoma 15.1 1.4
Leukaemia 13.6 3.0
Breast 13.5 13.0
NHL 13.3 3.2
Kidney 12.8 2.0
Pancreas 12.0 3.6
Lung 11.8 18.2
Oesophagus 11.2 2.7
Stomach 11.1 5.2
Uterus 11.0 1.4
Myeloma 10.3 1.6
Colon+rectum (+anus) 9.8 12.0
Bladder 7.3 2.9
Prostate 6.1 4.7
Total 83.9%
The variation in cancer burden per affected patient varies dramatically according
to tumour type. The mean AYLL is 12.5 years. The % YLL for each site is shown
for comparison (as Table 2). YLL¼years of life lost; AYLL¼avereage years of
life lost.
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Figure 3 Average years of life lost (AYLL) plotted against percentage of National Cancer Research Institute (NCRI) research spending. The dashed lines
show the mean percentage of NCRI spending (%) and the mean AYLL (12.5 years), for the tumour sites shown. The ‘Cinderella’ cancer sites, with the
highest individual cancer burden (AYLL) and lowest research spending, lie in the top left quadrant.
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The use of AYLL to indicate the impact of a tumour type on
individual patients considerably changes the ranking of the
mortality from different tumours (Table 3). The mean AYLL
amounts to 12.5 years, indicating the numerical average of the life
shortening from cancer. Prostate cancer, for example, has less
impact on this because it affects relatively older men and can run
an indolent course. In fact, it has the lowest AYLL of any of the
tumours shown, only 6.1 years. Brain tumour patients, however,
suffer more than three times as much loss of life, with an AYLL
figure of just over 20 years.
In Figure 3 AYLL is shown plotted against percentage of NCRI
research spending. In this diagram, tumour sites cluster rather
differently from Figure 2. The dashed lines show the means of
percentage of NCRI spending and AYLL, for the 17 tumour sites
shown. The top left quadrant contains those cancers with the
highest AYLL and the lowest research spending, which might
therefore be considered ‘Cinderella’ cancer sites. This diagram has
several notable features. The positions of breast cancer and
leukaemia, both of which have roughly the average AYLL, indicate
a considerable excess of research spending over individual cancer
burden. A higher research spend relative to AYLL is also directed
at colo-rectal and prostate cancers.
Of the four ‘Cinderella’ cancers, cervix is notable because of the
high AYLL despite cervical screening. Melanoma is noteworthy
because the percentage YLL is relatively modest for this tumour
type, accounting for only 1.4% of YLL, whereas the AYLL of just
over 15 years indicates that the impact per patient is rather high. It
is also increasing in incidence. However, perhaps the most striking
of all is that tumours of the brain and CNS have the highest AYLL
of all 17 tumour sites, but a rather modest 1.5% of NCRI research
spending. The ratio of research spending to AYLL is shown in
Table 4.
DISCUSSION
Using the YLL parameter, to represent population burden from
cancer, emphasises the discrepancy between research spending
and mortality. Although slightly more difficult to compute than
simple percentage mortality, this parameter has added value in
demonstrating the effect on the population for individual tumour
sites. The absolute differences between YLL and mortality are
comparatively small except for colo-rectal and breast cancers, and
to a lesser extent bladder and lung cancers. However, the relative
differences are much larger for many of the less common tumours
(Table 1). Consideration of YLL as a survival parameter might
therefore be important if cancer deaths from individual tumour
sites are to be used to make decisions concerning research support.
The biggest difference between the two indicators is seen for
tumours of the brain and CNS, and it is typically difficult to obtain
research funding in this area.
It may be that other public health decisions, such as the
provision of hospice care, would benefit from consideration of YLL
as a mortality indicator. For example, the biggest difference
between YLL and simple mortality applies to CNS and cervix
cancers, which have a substantial incidence in younger patients.
This might suggest the need to consider palliative care resources
for younger patients. These two tumour types also account for the
highest individual cancer burden, quantified by AYLL. Other
measures of social and personal burden, including quality of life,
might also be considered as part of a comprehensive review of
services.
The different indicators of cancer deaths, and cancer burden,
show different aspects of mortality, and are complementary.
Analysis of these together can identify tumour types with extreme
impact, either on society, for example through a high incidence, or
on individual patients as a result of relatively low cure rates.
Extreme tumour types, expressed by either statistic, may need
special consideration.
This analysis illustrates the value of considering different
mortality statistics, which include measures of the burden of
cancer deaths on both the population and individual patients. It
also demonstrates that inequity in resourcing research goes well
beyond the underprovision for lung cancer research. Overall, this
analysis suggests that a more subtle and comprehensive calculation
of mortality statistics would be useful in relation to research
funding, and debate on public health issues.
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6)
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Uterus 1.25 11.0 0.1
Brain+CNS 3.75 20.1 0.2
Pancreas 2.5 12.0 0.2
Oesophagus 2.5 11.2 0.2
Kidney 3.75 12.8 0.3
Stomach 3.75 11.1 0.3
Myeloma 3.75 10.3 0.4
Cervix 8.75 17.3 0.5
Melanoma 7.5 15.1 0.5
Bladder 3.75 7.3 0.5
Lung 8.75 11.8 0.7
Ovary 15.0 16.3 0.9
NHL 13.75 13.3 1.0
Colon+rectum (+anus) 30.0 9.8 3.1
Leukaemia 43.75 13.6 3.2
Breast 45.0 13.5 3.3
Prostate 21.25 6.1 3.5
Liver 3.75
Head and neck 5.0
Other 25.0
Total Bd250
Total NCRI spending amounts to approximately d250 million per year (NCRI, 2002).
The factor Annual NCRI research spending divided by AYLL represents the research
spending per YLL per patient with each cancer type. Figures for tumours of liver, head
and neck and ‘other’, which appear in the NCRI report, are shown. Sites are shown in
ascending order of spending per YLL. YLL¼years of life lost; AYLL¼avereage years
of life lost; NCRI¼National Cancer Research Institute.
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